ArticleBMC medicine2013
Recent findings on the health effects of omega-3 fatty acids and statins, and their interactions: do statins inhibit omega-3?
Article in BMC medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- Circulating Omega-3 Polyunsaturated Fatty Acids Levels in Coronary Heart Disease: Pooled Analysis of 36 Observational Studies.Nutrients · 2024Pooled it
- N-3 long-chain polyunsaturated fatty acids and risk of all-cause mortality among general populations: a meta-analysis.Scientific reports · 2016Pooled it
- Effect of Eicosapentaenoic and Docosahexaenoic Acids Added to Statin Therapy on Coronary Artery Plaque in Patients With Coronary Artery Disease: A Randomized Clinical Trial.Journal of the American Heart Association · 2017Trial
- Omega-3 PUFA supplementation and the response to evoked endotoxemia in healthy volunteers.Molecular nutrition & food research · 2014Trial
- Beneficial Effects of Omega-3 Fatty Acids on Obesity and Related Metabolic and Chronic Inflammatory Diseases.Nutrients · 2025Review
- Pharmacokinetic Interaction between Atorvastatin and Omega-3 Fatty Acid in Healthy Volunteers.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Childhood overeating is associated with adverse cardiometabolic and inflammatory profiles in adolescence.Scientific reports · 2021Article
- Hydroxymethylglutaryl Coenzyme a Reductase Inhibitors Differentially Modulate Plasma Fatty Acids in Rats With Diet-Induced-Hyperhomocysteinemia: Is ω-3 Fatty Acids Supplementation Necessary?Frontiers in physiology · 2019Article
- The Role ofNutrients · 2018Review
- Significance of long chain polyunsaturated fatty acids in human health.Clinical and translational medicine · 2017Review
- Cardioprotective effects of omega 3 fatty acids: origin of the variability.Journal of muscle research and cell motility · 2017Review
- Intake of polyunsaturated fat in relation to mortality among statin users and non-users in the Southern Community Cohort Study.Nutrition, metabolism, and cardiovascular diseases : NMCD · 2015Article
- Review
- Omega-3 Polyunsaturated Fatty Acids: The Way Forward in Times of Mixed Evidence.BioMed research international · 2015Review
- Article
- Helping women to good health: breast cancer, omega-3/omega-6 lipids, and related lifestyle factors.BMC medicine · 2014Review
- Neuropsychiatric adverse events associated with statins: epidemiology, pathophysiology, prevention and management.CNS drugs · 2014Review
- Wheat aleurone polyphenols increase plasma eicosapentaenoic acid in rats.Food & nutrition research · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early randomized controlled trials (RCTs) demonstrated the health benefits of omega-3 fatty acids (n-3), whereas recent RCTs were negative. We now address the issue, focusing on the temporal changes having occurred: most patients in recent RCTs are no longer n-3 deficient and the vast majority are now treated with statins. Recent RCTs testing n-3 against arrhythmias suggest that n-3 reduce the risk only in patients not taking a statin. Other recent RCTs in secondary prevention were negative although, in a post-hoc analysis separating statin users and non-users, non-significant protection of n-3 was observed among statin non-users whereas statin users had no effect. Recent RCTs testing statins - after the implementation of the New Clinical Trial Regulation in 2007 - are negative (or flawed) suggesting that the lack of effect of n-3 cannot be attributed to a parallel protection by statins. Finally, statins favor the metabolism of omega-6 fatty acids (n-6), which in turn inhibits n-3 and, contrary to n-3, they increase insulin resistance and the risk of diabetes. Thus, n-3 and statins are counteractive at several levels and statins appear to inhibit n-3.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.